Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Treace Medical Concepts (TMCI) Operating Income (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed Operating Income for 6 consecutive years, with -$5.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Income fell 2802.94% year-over-year to -$5.9 million, compared with a TTM value of -$54.2 million through Dec 2025, up 2.75%, and an annual FY2025 reading of -$54.2 million, up 2.75% over the prior year.
  • Operating Income was -$5.9 million for Q4 2025 at Treace Medical Concepts, up from -$15.7 million in the prior quarter.
  • Across five years, Operating Income topped out at -$204000.0 in Q4 2024 and bottomed at -$21.4 million in Q2 2024.
  • Average Operating Income over 5 years is -$10.6 million, with a median of -$11.6 million recorded in 2022.
  • The sharpest move saw Operating Income crashed 8566.67% in 2021, then surged 96.99% in 2024.
  • Year by year, Operating Income stood at -$5.6 million in 2021, then soared by 37.52% to -$3.5 million in 2022, then tumbled by 93.94% to -$6.8 million in 2023, then soared by 96.99% to -$204000.0 in 2024, then tumbled by 2802.94% to -$5.9 million in 2025.
  • Business Quant data shows Operating Income for TMCI at -$5.9 million in Q4 2025, -$15.7 million in Q3 2025, and -$17.0 million in Q2 2025.